Semaglutide downregulates the transcription factor PPARG, thereby reducing its inhibition of the downstream molecule ACSL1, leading to increased ACSL1 expression and promoting M1 polarization, ultimately enhancing the anti-tumor effects [95]
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a promising class of medications to address this underlying metabolic dysregulation that drives SLD
The clinical trial data behind the projections The projections for each medication are based on the landmark registration trials published in the New England Journal of Medicine
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al
These medications come in various forms, including name-brand medicines like Ozempic, Trulicity, and Victoza
, Lau, D